CD BioGlyco Unveils Revolutionary Glycan Microarray Assay for Enhanced Glycomics Research
CD BioGlyco Unveils Revolutionary Glycan Microarray Assay for Enhanced Glycomics Research
Share this Post to earn Money ( Upto ₹100 per 1000 Views )
CD BioGlyco, a leading provider of high-quality glycomics services, is excited to announce the launch of its state-of-the-art Glycan Microarray Assay, designed to accelerate discoveries in glycomics research and facilitate advancements in the understanding of complex carbohydrate structures. This cutting-edge platform is set to play a pivotal role in diverse fields, including drug discovery, biomarker identification, and the study of diseases linked to glycan abnormalities.
The Glycan Microarray Assay from CD BioGlyco offers an innovative approach to studying glycans, the sugar molecules that are vital to numerous biological processes, including immune response, cell signaling, and disease progression. By enabling scientists to analyze thousands of glycan interactions in parallel, this assay promises to uncover critical insights into the role of glycans in health and disease. The platform is equipped with a high-density microarray chip that contains a diverse range of glycans, allowing for detailed analysis of glycan-protein, glycan-cell, and glycan-antibody interactions.
Glycans are crucial to the regulation of immune function, pathogen recognition, and the development of therapeutic antibodies. However, their complex structures make them difficult to study using traditional techniques. CD BioGlyco’s Glycan Microarray Assay overcomes these challenges by providing an efficient, high-throughput platform for characterizing glycan interactions. This technology allows researchers to rapidly identify glycan-binding proteins, monitor glycosylation changes, and explore glycan-based biomarkers for a variety of diseases.
Up to now, CD BioGlyco provides glycan microarray constructs that include: covalently linked mono- (di-) glycan microarrays, non-covalently adsorbed polysaccharide microarrays, and oligosaccharide microarrays.
Based on the glycan microarray constructed, CD BioGlyco also provides detection services, covering 100 Glycan Microarray, 100 N-glycan Microarray, Sialic Acid Microarray, Microbial Glycan Microarray Assay, Human Milk Oligosaccharide (HMO) Microarray Assay, Sialylated Oligosaccharides Microarray Assay, Glycosaminoglycan (GAG) Microarray Assay...
“Glycomics research is becoming increasingly important, and our Glycan Microarray Assay is designed to meet the needs of scientists striving to make groundbreaking discoveries in this area,” said Anna, a representative speaker from CD BioGlyco. “We are proud to offer a tool that empowers researchers to better understand the role of glycans in biological processes. This technology not only accelerates research but also has the potential to contribute to the development of new therapeutic approaches for diseases like cancer, autoimmune disorders, and infectious diseases.”
For more information on the Glycan Microarray Assay and other glycomics services provided by CD BioGlyco, please visit https://www.bioglyco.com/glycan-microarray-assay.html.